Gritstone Oncology dividends
GRTS dividends
| Ex-dividend | Amount | Yield | Pay date | ||||
|---|---|---|---|---|---|---|---|
This company doesn't provide dividends. | |||||||
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The lead product candidate, GRANITE, is a personalized neoantigen-based immunotherapy. The second product candidate, SLATE, is a shared neoantigen (“off-the-shelf”) immunotherapy. The company has developed its product candidates using two key pillars—a proprietary machine learning-based platform, Gritstone EDGE™, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient's tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients' TSNA to drive the patient's immune system to attack and destroy tumors.
Learning section - What Is a Dividend?
A dividend is the distribution of reward from a portion of the company's earnings and is paid to a class of its shareholders. Dividends are decided and managed by the company's board of directors, though they must be approved by the shareholders through their voting rights